Latest filing published 16 Sept 2026 for Devyser Diagnostics AB, €4,767.
Based on 5 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This profile gathers the share dealings of Jan Wahlström in Devyser Diagnostics AB. Between 1 September 2025 and 15 September 2026, the trades on record add up to 10 filings.
On the market, this insider has only ever bought: 10 purchases, €184k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2026 alone, the filings show 8 purchases and no sales.
In size, the median ticket on the buying side is €15k. Relative to company size, the median is 0.016% of market cap (9 purchases with a known value). 1 out of 9 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster. For 5 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 0% of cases, with a median move of -40.0%. Past outcomes like these are no guarantee of what comes next.
The latest filing, published on 16 September 2026, reports an open-market purchase of €4,767 in Devyser Diagnostics AB. Filings reach the Finansinspektionen feed a median of 2 days after the trade. The regulation allows three business days to notify a trade (MAR article 19). This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations